lanifibranor (IVA337) / Inventiva, Hepalys Pharma 
Welcome,         Profile    Billing    Logout  
 2 Diseases   2 Trials   2 Trials   202 News 


«1234
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) -  Nov 4, 2019   
    P2b,  N=247, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  lanifibranor (IVA337) / Inventiva
    The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_2652;    
    Mechanistically, we propose that agonism of different PPAR isoforms in the pulmonary circulation results in exaggerated EC proliferation after SU5416 leading to paradoxical worsening of PH, but protection from the right ventricular hypertrophy that occurred in control mice. Thus, the right ventricular outcomes in our study suggest that there might be protection against RV dilatation and hypertrophy in other forms of murine PH and in human PAH that may positively impact on clinical outcome
  • ||||||||||  Triglide (fenofibrate) / Vectura, Shionogi, Lacromid (bezafibrate) / Remedica
    HUMAN-DERIVED HEPATIC IN VITRO MODELS IDENTIFY DISTINCT ANTI-NASH EFFICACIES OF PPAR-AGONISTS (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2005;    
    Elafibranor, followed by pioglitazone, showed the strongest anti-‘NASH’ activity in all in vitro systems tested. The effects were most firmly unveiled by PHH and stem cells and correspond to current clinical guidelines and patient trial results.
  • ||||||||||  Journal:  An update on the recent advances in antifibrotic therapy. (Pubmed Central) -  Jul 17, 2019   
    Expert commentary: The tremendous advances in translational and clinical research fuels the hope for efficacious antifibrotic therapies within the next 5 years. Very likely, a combination of etiology-specific, metabolic, anti-inflammatory and direct anti-fibrotic interventions will be most effective.
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Trial completion date, Trial primary completion date:  Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Apr 19, 2019   
    P2,  N=84, Recruiting, 
    In vitro and in vivo, compound 5 demonstrated strong activity in models that are relevant to NonAlcoholic SteatoHepatitis (NASH) pathophysiology suggesting therapeutical potential for NASH patients. Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Trial primary completion date:  FASST: Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) -  Mar 4, 2019   
    P2,  N=145, Completed, 
    Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Trial completion date, Trial primary completion date:  NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) -  Dec 13, 2018   
    P2b,  N=225, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Enrollment open:  Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Sep 5, 2018   
    P2,  N=74, Recruiting, 
    Trial completion date: Feb 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Dec 2019 Not yet recruiting --> Recruiting
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Trial primary completion date, IO biomarker:  NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) -  Jan 3, 2018   
    P2b,  N=225, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Jan 2019
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    Enrollment open, IO biomarker:  NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) -  Jan 31, 2017   
    P2b,  N=225, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  lanifibranor (IVA337) / Inventiva, Hepalys Pharma
    New P2b trial, IO biomarker:  NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) -  Jan 3, 2017   
    P2b,  N=225, Not yet recruiting,